Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - A pooled analysis

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 9, 2011, Pages 1115-1122

  Leifeld, L ^a   Pfutzer R ^a   Morgenstern, J ^a   Gibson, P R ^b   Marakhouski, Y ^c   Greinwald, R ^d   Mueller, R ^d   Kruis, W ^a  

^a Evangelisches Krankenhaus Kalk   (Germany)

^b MONASH UNIVERSITY   (Australia)

^c BELARUSIAN MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Belarus)

^d Dr Falk Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EUDRAGIT; MESALAZINE;

ABDOMINAL PAIN; ADULT; ALLERGIC REACTION; ARTICLE; COLITIS; COLONOSCOPY; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG GRANULE; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; HEARING LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASLES; NAUSEA; NEPHRITIS; PANCOLITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROCTOSIGMOIDITIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RHINOPHARYNGITIS; TABLET FORMULATION; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRAL UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; POLYMETHACRYLIC ACIDS; POWDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME;

EID: 80053958666     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04840.x     Document Type: Article

References (25)

1. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005; 54: 960-5. (Pubitemid 40873909)
2. Travis SPL, Stange EF, Lémann M, et al. European evidence-based Consensus on the management of ulcerative colitis: current management. J Crohn Colitis 2008; 2: 24-62. (Pubitemid 351179488)
3. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 1998; 41: 93-7. (Pubitemid 28044882)
4. Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol 1996; 91: 1338-42. (Pubitemid 26236365)
5. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71. (Pubitemid 27440908)
6. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 2003; 1: 36-43. (Pubitemid 37254470)
7. Marakhouski Y, Fixa B, Holoman J, et al. A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 133-40. (Pubitemid 40227447)
8. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised non-inferiority trial. Gut 2009; 58: 233-40.
9. Gibson PR, Fixa B, Pekarkova B, et al. Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 1017-26.
10. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from (153)Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003; 17: 1163-9. (Pubitemid 36605753)
11. Rachmilewitz D,. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6. (Pubitemid 19032930)
12. Bergman R, Parkes M,. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 841-55.
13. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75. (Pubitemid 46108735)
14. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102. (Pubitemid 46096842)
15. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix™ mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007; 26: 205-15. (Pubitemid 46985493)
16. Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005; 11: 421-7. (Pubitemid 40704075)
17. Desreumaux P, Ghosh S,. Review article: mode of action and delivery of 5-aminosalicylic acid-new evidence. Aliment Pharmacol Ther 2006; 24: 2-9. (Pubitemid 44267773)
18. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 39-43. (Pubitemid 36126514)
19. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33. (Pubitemid 32959535)
20. Kane SV,. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
21. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44. (Pubitemid 36875345)
22. Shale MJ, Riley SA,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8. (Pubitemid 36951655)
23. Levy RL, Feld AD,. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 1733-42. (Pubitemid 29315874)
24. Moody GA, Jayanthi V, Probert CSJ, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83. (Pubitemid 26413548)
25. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005; 54: 1573-8. (Pubitemid 41531774)